These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30332747)

  • 1. DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome.
    Feki A; Hibaoui Y
    Brain Sci; 2018 Oct; 8(10):. PubMed ID: 30332747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
    De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
    Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome.
    Lana-Elola E; Aoidi R; Llorian M; Gibbins D; Buechsenschuetz C; Bussi C; Flynn H; Gilmore T; Watson-Scales S; Haugsten Hansen M; Hayward D; Song OR; Brault V; Herault Y; Deau E; Meijer L; Snijders AP; Gutierrez MG; Fisher EMC; Tybulewicz VLJ
    Sci Transl Med; 2024 Jan; 16(731):eadd6883. PubMed ID: 38266108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
    Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
    J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
    Çağlayan ES
    Cell Biol Int; 2016 Dec; 40(12):1256-1270. PubMed ID: 27743462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
    Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
    Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.
    Stringer M; Goodlett CR; Roper RJ
    Mol Genet Genomic Med; 2017 Sep; 5(5):451-465. PubMed ID: 28944229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment.
    De Toma I; Ortega M; Aloy P; Sabidó E; Dierssen M
    Front Mol Neurosci; 2019; 12():272. PubMed ID: 31803016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
    McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
    Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
    Nguyen TL; Duchon A; Manousopoulou A; Loaëc N; Villiers B; Pani G; Karatas M; Mechling AE; Harsan LA; Limanton E; Bazureau JP; Carreaux F; Garbis SD; Meijer L; Herault Y
    Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DYRK1A: a potential drug target for multiple Down syndrome neuropathologies.
    Becker W; Soppa U; Tejedor FJ
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):26-33. PubMed ID: 24152332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.
    Duchon A; Herault Y
    Front Behav Neurosci; 2016; 10():104. PubMed ID: 27375444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.
    Hawley LE; Prochaska F; Stringer M; Goodlett CR; Roper RJ
    Pharmacol Biochem Behav; 2022 Jun; 217():173404. PubMed ID: 35576991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
    Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
    Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
    Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
    Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues.
    London J; Rouch C; Bui LC; Assayag E; Souchet B; Daubigney F; Medjaoui H; Luquet S; Magnan C; Delabar JM; Dairou J; Janel N
    Mol Neurobiol; 2018 May; 55(5):3822-3831. PubMed ID: 28540658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models.
    Souchet B; Guedj F; Penke-Verdier Z; Daubigney F; Duchon A; Herault Y; Bizot JC; Janel N; Créau N; Delatour B; Delabar JM
    Front Behav Neurosci; 2015; 9():267. PubMed ID: 26539088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DYRK1a Inhibitor Mediated Rescue of
    Zhu B; Parsons T; Stensen W; Mjøen Svendsen JS; Fugelli A; Hodge JJL
    Front Pharmacol; 2022; 13():881385. PubMed ID: 35928283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.